glp-1 and insulin resistance Receptor Agonists as Treatments for Type 2 Diabetes Adipose Tissue: A Novel Target
Description
Such use may be motivated by personal preferences, GI tolerability, costs, and drug shortages
Injections win for consistent dosing and trial-backed schedules
Savidge TC, Newman P, Pothoulakis C, et al
See Figure 1
doi: 10.1002/14651858.CD012990.pub2 84
The fix: Space fiber supplements at least 2 hours from other medications
